Medicus Pharma subsidiary signs co-development deal with Pfizer for antibody-drug conjugate
Medicus Pharma Inc. licensed rights to Pfizer's early clinical-stage asset CD228V, agreeing to pay up to $27 million in near-term fees plus potential milestones exceeding $1 billion.
SEC filing